WO2000062787A1 - Methodes et compositions destinees a la potentialisation de la presentation de l'antigene au moyen de cellules de presentation d'antigene - Google Patents

Methodes et compositions destinees a la potentialisation de la presentation de l'antigene au moyen de cellules de presentation d'antigene Download PDF

Info

Publication number
WO2000062787A1
WO2000062787A1 PCT/US2000/009664 US0009664W WO0062787A1 WO 2000062787 A1 WO2000062787 A1 WO 2000062787A1 US 0009664 W US0009664 W US 0009664W WO 0062787 A1 WO0062787 A1 WO 0062787A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
iss
cells
odn
apcs
Prior art date
Application number
PCT/US2000/009664
Other languages
English (en)
Inventor
Eyal Raz
Elena Martin-Orozco
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to AU46426/00A priority Critical patent/AU4642600A/en
Publication of WO2000062787A1 publication Critical patent/WO2000062787A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG

Definitions

  • the invention relates to methods and oligonucleotide compositions for use in enhancing the antigen- presentation activity of cells which have antigen-presentation capabilities.
  • APCs antigen-presentmg cells
  • lymphocytes play a crucial role in the primary activation of T cells to respond to antigen. These interactions are coordinated by upregulation of MHC, adhesion and co-stimulatory molecules on the surface of antigen-stimulated cells with antigen-presentation capabilities (e.g., dendritic cells, macrophages, B cells and tumor cells), as well as by contact with cytokmes. Without the contribution of these varying factors, T cells can respond to antigen stimulation (especially by weakly lmmunogemc antigens) by developing tolerance rather than reactivity.
  • APCs antigen-presentmg cells
  • tumor antigen vaccine administration can lead to T cell tolerance, thus minimizing the efficacy of the vaccine in counte ⁇ ng tumor development.
  • T cell tolerance is believed to be the result, in part, of the absence of co-stimulatory signals (e.g., binding by T cells of B7 hgand on APCs).
  • co-stimulatory signals e.g., binding by T cells of B7 hgand on APCs.
  • B7 transduced tumor cells are being studied for use as anti-cancer vaccines, with mixed success.
  • the invention provides methods for upregulating the expression of certain cell surface molecules on cells capable of antigen-presentation (e.g. , B cells and macrophages; collectively, "APCs”), thereby enhancing the antigen-presenting activity of such cells, as compared to levels of expression observed in unstimulated and antigen-stimulated cells.
  • the enhancement of antigen-presenting activity in such cells (“APC-activation” of the cells) is provided by contacting the cells with an immunostimulatory oligonucleotide (ISS) and can be achieved not only in cells pre-primed with ISS before contact with antigen, but also in cells contacted with ISS and antigen in combination.
  • APC-activation of target cells in turn enhances primary activation of T cells to react against, rather than develop tolerance toward, antigen.
  • ISS enhance the capacity of affected macrophages to take up antigen (through upregulation of Fc ⁇ R expression), present antigen (through upregulation of MHC Class I and II as well as CD Id expression), produce co- stimulatory factors (B7 and CD40), provide cell-to-cell adhesion (through upregulation of ICAM expression) and increase Thl stimulatory cytokine production (e.g. , IL-12).
  • expression of MHC Class I and II molecules, B7-2, CD40, ICAM, IFN- ⁇ R and IL-2R by B cells is increased by ISS contact.
  • APC-activation of target cells in turn enhances activation of T cells to respond to presented antigen.
  • An especially useful application of this aspect of the invention is in cancer immunotherapy, wherein activation of tumor antigen reactive T cells is enhanced, thereby improving the prospects for T cell immunotherapy against tumor cells.
  • ISS are used to enhance the tumor antigen presenting capacity of tumor cells.
  • APC-activated tumor cells have a proportionally greater impact on stimulation of the host protective immune response.
  • tumor cells treated with ISS ex vivo are useful as vaccines through remtroduction into a host
  • the invention also provides cells and compositions based on such cells which have been APC- activated according to the invention, including macrophages, B cells, dendritic cells and tumor cells.
  • FIG. 1 In vitro induction of cell surface molecules on mouse splenic B cells.
  • 1A and IB Spleen cells (2xl0 6 /well) from BALB/c mice were cultured with ISS-ODN (1 ⁇ g/ml), M-ODN (1 ⁇ g/ml), or media alone for 48 hours and then stained for B220 (PE) and activation markers (FITC) for FACS analysis The histograms represent the FITC staining of gated PE + B220 + B cells. The numbers on the right side of the histogram represent the percentage of positive cells in comparison to the media control.
  • PE B220
  • FITC activation markers
  • mice were sacrificed on days 2, 7, and 21 after injection, the spleens were harvested, and the cells were stained for expression of B220 (PE) and the activation markers (FITC) for FACS analysis
  • PE B220
  • FITC activation markers
  • the histograms represent the FITC staining of gated PE + B cells
  • the numbers in the upper left represent the mean fluorescence, which was used to compare expression levels per cell for the markers that are expressed constitutively in >95% of the cells. Data are representative of the results obtained from 3 different mice per group.
  • FIG. 3 Inhibition ofB cell proliferation does not effect B cell surface molecule expression
  • spleen cells were gamma irradiated (1500 rad) or MMC-treated (50 ⁇ g/ml) and then incubated with ISS-ODN (1 ⁇ g/ml) plus BrdU (15 ⁇ g/ml) After 48 hours incubation, cells were stained for B220 (PE) and the activation markers (FITC) checked by FACS analysis. The histograms represent the FITC staining of gated PE + B cells. "Untr" represents untreated cells, MMC represents mitomycin-treated cells and "Irrad” represents irradiated cells.
  • the numbers on the right side of the histogram represent the percentage of positive cells in comparison to the media control.
  • the numbers in the upper left represent the mean fluorescence, which was used to compare expression levels per cell for the markers that are expressed constitutively in >95% of the cells. Data are represent values from 3 independent experiments.
  • FIG. 4 In vitro pUC19 activation of splenic B cell surface molecule expression Spleen cells (2xl0 6 /well) were transfected (using DOTAP) with pUC19 (10 ⁇ g/ml) for 4 hours, then washed and incubated for additional 48 hours in culture media and then stained for B220 (PE) and activation markers (FITC) for FACS analysis.
  • the histograms represent the FITC staining of gated PE + B cells.
  • the numbers on the right side of the histogram represent the percentage of positive cells in comparison to the media control.
  • the numbers in the upper left represent the mean fluorescence, which was used to compare expression levels per cell for the markers that are expressed constitutively in >95% of the cells. Data represent values from 3 different experiments.
  • FIG. 5 Bone marrow derived macrophage (BMDM) cytokine and surface molecule expression profiles induced by ISS
  • BMDM Cytokine profile obtained from BMDM.
  • BMDM (2xl0 5 /ml) were cultured in vitro with ISS-ODN (1 ⁇ g/ml), M-ODN (1 ⁇ g/ml), pUC19 (lO ⁇ g/ml), LPS (5 ⁇ g/ml), or media alone. The supernatant were collected after 48 hours Cytokine concentrations (IL-6, IL-12, TNF- ⁇ and IFN- ⁇ ) were measured by ELISA. No detectable levels of TNF- ⁇ and IFN- ⁇ were observed in this assay Data represent mean+SE from 3 different expe ⁇ ments.
  • FIG. 6 APCs pre-primed with ISS in vivo efficiently activate naive T cells in vitro T cell receptor-ovalbumm encoding transgenic (TCR-OVA TG) mice were injected l.d. with ISS- ODN or M-ODN or salme. Naive T cells from TCR-OVA TG mice (lOVwell) were mixed with the same number of accessory cells (APCs) obtained from ISS-ODN, M-ODN or saline injected mice, and different concentrations of OVA for 4 days.
  • TCR-OVA TG mice T cell receptor-ovalbumm encoding transgenic mice were injected l.d. with ISS- ODN or M-ODN or salme.
  • Naive T cells from TCR-OVA TG mice (lOVwell) were mixed with the same number of accessory cells (APCs) obtained from ISS-ODN, M-ODN or saline injected mice, and different concentrations of OVA for 4 days.
  • T cell proliferation assay the cultures were incubated with [ 3 H] thymidme (1 ⁇ Ci per well) for 18 hours and cells were harvested and [ 3 H] thymidine incorporation was determined.
  • Figure 7 Effect of ISS-ODN pre-priming on the subsequent T cell response to ⁇ -galactosidase in vivo
  • mice were injected l.d. with ISS-ODN or M-ODN 3 days prior to ⁇ -gal injection or co-injected with ISS-ODN/ ⁇ -gal, M-ODN/ ⁇ -gal or ⁇ -gal alone.
  • telomeres Upon antigen encounter, the activated APCs interact with naive Th cells.
  • Cancer vaccines have been thought to have promise because, unlike most protective vaccines, they are therapeutic; i.e., they elicit immune responses against antigens (tumor antigens) in residence m the host on target cells.
  • a primary goal is to introduce a tumor antigen (one present on the target tumor cells) to cells with the capability to present antigen to T cells to induce T cell reactivity to the antigen.
  • the efficacy of activation is intimately tied to the density of peptide/MHC complexes displayed on APCs and the particular costimulatory molecules expressed by APCs.
  • peptide antigens recognized by T cell epitopes tend to be inefficiently presented, leading to T cells of relatively low antigen reactivity.
  • potentiation of APC-activation of cells to enhance their capacity to present antigen to T cells is directly correlative with an improvement in T cell reactivity to the presented antigen.
  • This aspect of the invention has significant consequences for the efficacy of T cell-mediated immunotherapies, such as is practiced through use of anti-tumor vaccines.
  • an ISS-ODN is administered together with the anti-tumor vaccine to serve as an APC activator.
  • the ISS-ODN may be co-admmistered with the vaccine, administered before vaccination or conjugated to a component of the vaccine (e.g., to the peptide tumor antigen)
  • the ISS-ODN may be used as an APC activator in conjunction with ex vivo cancer immunotherapy with tumor-antigen expressing cells treated with ISS.
  • ISS-ODN administered according to the invention act as APC activators and modulate the host immune response to an antigen m ways which include: (1) potentiation of the capacity of affected bone-marrow de ⁇ ved cells (e.g., macrophages) to take up antigen (through upregulation of Fc ⁇ R expression), present antigen (through upregulation of MHC Class I and II as well as CD Id expression), produce co-stimulatory factors (B7 and CD40), provide cell-to-cell adhesion (through upregulation of ICAM expression) and increase Thl stimulatory cytokine production (e.g., IL-12);
  • affected bone-marrow de ⁇ ved cells e.g., macrophages
  • present antigen through upregulation of MHC Class I and II as well as CD Id expression
  • B7 and CD40 co-stimulatory factors
  • Thl stimulatory cytokine production e.g., IL-12
  • Thl stimulatory cytokine production e.g., IL-12
  • B7-2, CD40, ICAM, IFN- ⁇ R and IL-2R B cells (splenic and naive peripheral cells); and, (4) enhancement of primary activation of T cells to respond to presented antigen.
  • An "enhanced" T cell mediated immune response is one produced by an APC activator of the invention; i.e., more potent antigen-specific T cell activation and reactivity to an antigen than is induced by a control, generally consisting of the antigen administered alone or with a conventional adjuvant.
  • a six-fold (approximate) improvement in some aspects of T cell activation and antigen reactivity can be achieved according to the invention.
  • Core nucleotide sequence refers to the motif of at least six nucleotides, including at least one unmethylated CpG motif, which is present in the ISS-ODN of the invention.
  • the relative position of each CpG sequence in ISS-ODN with immunostimulatory activity in certain mammalian species is 5'-CG-3' (i.e., the C is in the 5' position with respect to the G in the 3' position).
  • ISS-ODN flank the CpG motif with at least two pu ⁇ ne nucleotides (e.g., GA or AA) and at least two pyrimidme nucleotides (5'-Pur ⁇ ne-Pu ⁇ ne-[C]-[G]-Py ⁇ m ⁇ dme-Pyr ⁇ m ⁇ dme-3')
  • ISS-ODN enhance the APC function of target cells via the induction of different categories of cell surface molecules.
  • the up-regulation of cell surface molecules on APCs involved m antigen uptake (Fc ⁇ R), antigen presentation (MHC class I, class II, and CD Id), costimulation (B7 and CD40), and cell-cell adhesion (ICAM-1) combined with cytokme production (TNF, IFNs and IL-12), provide the basis of the strong Thl adjuvant properties and for the pre- p ⁇ mmg effect observed for ISS-ODN (see, outline of proposed mechanism of action of ISS-ODN as APC activators shown m Figure 8A and B). These activities would be expected to suppress pathogen replication, enhance pathogen-derived antigen presentation, activate humoral and cell mediated specific immunity, and instruct the adaptive immune system to generate a Thl response against an invading microbe.
  • the uptake of antigen is enhanced by ISS-ODN mediated up-regulation of the Fc ⁇ receptors (CD 16/32) while antigen presentation is enhanced by the up-regulation of classical MHC class I and class II molecules ( Figures 1-2), as well as non-classical MHC molecules (CD Id; in vivo, Figure 2).
  • ISS-ODN also reduce the threshold number of cognate (cell-to-cell) interactions required for APC activation of lymphocytes by selectively enhancing the expression of ICAM-1 adhesion molecules (Figure 1-2). ICAM-1 binding to its hgand LFA-1 stabilizes interactions between APCs and lymphocytes. Furthermore, ISS-ODN up-regulate the expression of the costimulatory molecules B7 and CD40 on B cells and macrophages. These molecules play a major role in T cell p ⁇ ming, activation, and differentiation via interactions with their specific receptors, CD28 and CD40L, respectively, on naive T cells.
  • ISS-ODN stimulated APCs T cell proliferation in response to a model allergemc antigen (ovalbumm, or "OVA" in naive and ISS-ODN p ⁇ med animals.
  • OVA allergemc antigen
  • ISS-ODN pre-p ⁇ mmg enhanced the subsequent T cell prohferative response to OVA of naive OVA TCR TG T cells by 4 fold ( Figure 6B).
  • OVA specific IFN- ⁇ secretion was induced (in vitro), indicating the differentiation of naive Th cells (OVA TCR TG Th cells) toward a Thl phenotype (Figure 6A).
  • the pre-p ⁇ mmg of APCs with ISS-ODN instructs and biases the subsequent Th response to a Thl type, emphasizing the instructive role of innate immunity (i.e., APCs) in the development of the adaptive immune response.
  • APCs innate immunity
  • ISS-ODN are non-codmg ohgonucleotides having six or more nucleotides that may include at least one unmethylated CpG motif.
  • the relative position of each CpG sequence in ISS- ODN with immunostimulatory activity in certain mammalian species is 5'-CG-3' (i.e , the C is m the 5' position with respect to the G m the 3' position).
  • ISS-ODN flank the CpG motif with at least two pu ⁇ ne nucleotides (e.g., GA or AA) and at least two pyrimidme nucleotides (5'-Pur ⁇ ne-Pu ⁇ ne-[C]-[G]-Py ⁇ m ⁇ dme-Py ⁇ m ⁇ d ⁇ ne-3').
  • CpG motif-contammg ISS-ODN are believed to stimulate B lymphocyte proliferation (see, e.g., Krieg, et al , Nature, 374:546-549, 1995).
  • ISS-ODN may be flanked upstream and/or downstream by any number or composition of nucleotides or nucleosides.
  • ISS-ODN are at least 6 mer m length, and preferably are between 6 and 200 mer in length, to enhance uptake of the ISS-ODN into target tissues.
  • Those of ordinary skill in the art will be familiar with, or can readily identify, reported nucleotide sequences of known ISS-ODN. For ease of reference in this regard, the following sources are especially helpful:
  • ISS-ODN useful in the invention include those which have the following hexameric nucleotide sequences:
  • DNA based ISS-ODN useful in the invention include those which have the following hexameric nucleotide sequences:
  • AACGTT AGCGTC, GACGTT, GGCGTT, AACGTC, AGCGTC, GACGTC, GGCGTC, AACGCC, AGCGCC, GACGCC, GGCGCC, AGCGCT, GACGCT, GGCGCT, TTCGAA, GGCGTT and AACGCC (respectively, SEQ.ID.Nos.1-18).
  • ISS-ODN may be single-stranded or double-stranded DNA, single or double-stranded RNA and/or oligonucleosides.
  • the ISS-ODN may or may not include palindromic regions. If present, a palindrome may extend only to a CpG motif, if present, in the core hexamer sequence, or may encompass more of the hexamer sequence as well as flanking nucleotide sequences.
  • nucleotide bases of the ISS-ODN which flank the CpG motif of the core hexamer and/or make up the flanking nucleotide sequences may be any known naturally occurring bases or synthetic non- natural bases (e.g., TCAG or, in RNA, UACGI). Oligonucleosides may be incorporated into the internal region and/or termini of the ISS-ODN using conventional techniques for use as attachment points for other compounds (e.g., peptides).
  • the base(s), sugar moiety, phosphate groups and termini of the ISS-ODN may also be modified in any manner known to those of ordinary skill in the art to construct an ISS-ODN having properties desired m addition to the desc ⁇ bed activity of the ISS- ODN.
  • sugar moieties may be attached to nucleotide bases of ISS-ODN in any ste ⁇ c configuration.
  • backbone phosphate group modifications e.g., methylphosphonate, phosphorothioate, phosphoroamidate and phosphorodithioate lnternucleotide linkages
  • backbone phosphate group modifications can confer anti-microbial activity on the ISS-ODN and enhance their stability in vivo, making them particularly useful m therapeutic applications.
  • a particularly useful phosphate group modification is the conversion to the phosphorothioate or phosphorodithioate forms of the ISS-ODN ohgonucleotides.
  • phosphorothioates and phosphorodithioates are more resistant to degradation in vivo than their unmodified oligonucleotide counterparts, making the ISS-ODN of the invention more available to the host.
  • ISS-ODN can be synthesized using techniques and nucleic acid synthesis equipment which are well- known in the art. For reference in this regard, see, e.g., Ausubel, et al, Current Protocols in Molecular Biology, Chs. 2 and 4 (Wiley Interscience, 1989); Mamatis, et al, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab., New York, 1982); U.S. Patent No. 4,458,066 and U.S. Patent No. 4,650,675. These references are incorporated herein by reference for the sole purpose of demonstrating knowledge in the art concerning production of synthetic ohgonucleotides. Because the ISS-ODN is non-coding, there is no concern about maintaining an open reading frame du ⁇ ng synthesis.
  • ISS-ODN or ISS ennched DNA may be isolated from microbial species (especially mycobacte ⁇ a) using techniques well-known in the art, such as nucleic acid purification or hybridization.
  • microbial species especially mycobacte ⁇ a
  • such isolated ISS-ODN will be purified to a substantially pure state; i.e., to be free of endogenous contaminants, such as hpopolysaccha ⁇ des.
  • ISS-ODN isolated as part of a larger polynucleotide can be reduced to the desired length by techniques well known in the art, such as by endonuclease digestion.
  • the ISS-ODN APC activators of the invention will take the form of free ISS-ODN ohgonucleotides, ISS-ODN ohgonucleotide-peptide conjugates and ISS- containing recombinant expression vectors (data regarding the activity of ISS-ODN conjugates and ISS-ODN vectors are set forth in co-pendmg, commonly assigned U.S. patent applications Serial Nos. 60/028,118 and 08/593,554; data from which is incorporated herein by reference to demonstrate ISS-ODN immunostimulatory activity in vivo).
  • antigen may be co- delivered (separately or in an admixture with free ohgonucleotides), expressed recombmanfly from a plasmid (especially one containing the ISS-ODN moiety in the backbone) or conjugated to an antigen.
  • conjugate partners include any lmmunogemc antigen (including allergens, live and attenuated viral particles and tumor antigens), targeting peptides (such as receptor hgands, antibodies and antibody fragments, hormones and enzymes), non-peptidic antigens (coupled via a peptide linkage, such as hpids, polysaccha ⁇ des, glycoprotems, ganghosides and the like) and cytokmes (including mterleukms, interferons, erythropoietm, tumor necrosis factor and colony stimulating factors).
  • Such conjugate partners can be prepared according to conventional techniques (e.g., peptide synthesis) and many are commercially available.
  • Conjugation can be accomplished at either termini of the ISS-ODN or at a suitably modified base m an internal position (e.g., a cytosme or uracil).
  • a suitably modified base m an internal position (e.g., a cytosme or uracil).
  • methods for conjugating ohgonucleotides to proteins and to ohgosaccha ⁇ de moieties of Ig are known (see, e.g., O'Shannessy, et al, J.
  • Kessler “Nonradioactive Labeling Methods for Nucleic Acids", in Kricka (ed.), Nonisotopic DNA Probe Techniques (Acad.Press, 1992)).
  • suitable conjugation methods include: conjugation through 3' attachment via solid support chemistry (see, e.g., Haralambidis, et al, Nuc.Acids Res., 18:493 (1990) and Haralambidis, et al, Nuc Acids Res., 18:501 (1990) [solid support synthesis of peptide partner]; Zuckermann, et al, Nuc.Acids Res , 15:5305 (1987), Corey, et al, Science, 238: 1401 (1987) and Nelson, et al, Nuc. Acids Res., 17:1781 (1989) [solid support synthesis of oligonucleotide partner]).
  • Ammo-ammo group linkages may be performed as described in Benoit, et al , Neuromethods, 6:43 (1987), while fhiol-carboxyl group linkages may be performed as desc ⁇ bed m Smah, et al, Oligonucleotide Analogues: A Practical Approach (IRL Press, 1991).
  • the oligonucleotide partner is synthesized on a solid support and a linking group compnsmg a protected amine, thiol or carboxyl group opposite a phosphoramidite is covalently attached to the 5'-hydroxyl (see, e.g., U.S. Patent Nos. 4,849,513; 5,015,733; 5,118,800 and 5,118,802).
  • Linkage of the oligonucleotide partner to a peptide may also be made via incorporation of a linker arm (e.g., amme or carboxyl group) to a modified cytosme or uracil base (see, e.g., Ruth, 4th Annual Congress for Recombinant DNA Research at 123).
  • Affinity linkages e.g., biotin-streptavidin
  • Roget, et al, Nuc.Acids Res., 17:7643 (1989) may also be used (see, e.g., Roget, et al, Nuc.Acids Res., 17:7643 (1989)).
  • Methods for linking ohgonucleotides to pids include synthesis of ohgo- phosphohpid conjugates (see, e.g., Yanagawa, et al, Nuc. Acids Symp.Ser., 19:189 (1988)), synthesis of ohgo-fatty acids conjugates (see, e.g., Grabarek, et al, Anal.Biochem., 185: 131 (1990)) and o go- sterol conjugates (see, e.g., Boujrad, et al, Proc.Natl.Acad.Sci USA, 90:5728 (1993)).
  • Co-admmistration of a peptide drug with an ISS-ODN may also be achieved by incorporating the ISS-ODN in cis or in trans into a recombinant expression vector (plasmid, cosmid, virus or retrovirus) which codes for any therapeutically beneficial protein deliverable by a recombinant expression vector.
  • a recombinant expression vector plasmid, cosmid, virus or retrovirus
  • incorporation of an ISS-ODN into an expression vector for use in practicing the invention is desired, such incorporation may be accomplished using conventional techniques which do not require detailed explanation to one of ordinary skill m the art. For review, however, those of ordinary skill may wish to consult Ausubel, Current Protocols in Molecular Biology, supra.
  • telomeres are constructed using standard hgation techniques.
  • the hgation mixtures may be used to transform a host cell and successful transformants selected by antibiotic resistance where appropriate.
  • Vectors from the transformants are prepared, analyzed by restriction and/or sequenced by, for example, the method of Messing, et al , (Nucleic Acids Res., 9:309, 1981), the method of Maxam, et al , (Methods in Enzymology, 65:499, 1980), or other suitable methods which will be known to those skilled in the art. Size separation of cleaved fragments is performed using conventional gel electrophoresis as described, for example, by Mamatis, et al , (Molecular Cloning, pp. 133-134, 1982).
  • Host cells may be transformed with expression vectors and cultured in conventional nutrient media modified as is appropriate for inducing promoters, selecting transformants or amplifying genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • plasmids and cosmids are particularly preferred for their lack of pathogenicity.
  • plasmids and cosmids are subject to degradation in vivo more quickly than viruses.
  • viral vectors that can be utilized m the invention include adenovirus, adeno-associated virus, herpes virus, vaccinia or an RNA virus such as a retrovirus.
  • adeno-associated viruses would possess the advantage of low pathogenicity. The relatively low capacity of adeno-associated viruses for insertion of foreign genes would pose no problem in this context due to the relatively small size m which ISS-ODN of the invention can be synthesized.
  • the techniques for making phosphate group modifications to ohgonucleotides are known in the art and do not require detailed explanation.
  • the intermediate phosphate triester for the target oligonucleotide product is prepared and oxidized to the naturally occurring phosphate triester with aqueous iodine or with other agents, such as anhydrous amines.
  • the resulting oligonucleotide phosphoramidates can be treated with sulfur to yield phophorothioates.
  • ISS-ODN may be prepared m a pharmaceutically acceptable composition.
  • Pharmaceutically acceptable earners preferred for use with the ISS-ODN of the invention may include sterile aqueous of non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and mjectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/ aqueous solutions, emulsions or suspensions, including salme and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelatmg agents, and inert gases and the like.
  • a composition of ISS-ODN may also be lyophihzed using means well known in the art, for subsequent reconstitution and use according to the invention.
  • Absorption promoters, detergents and chemical irritants can enhance transmission of an ISS-ODN composition into a target tissue.
  • absorption promoters and detergents which have been used with success in mucosal delivery of organic and peptide-based drugs, see Chien, Novel Drug Delivery Systems, Ch. 4 (Marcel Dekker, 1992).
  • Suitable nasal absorption promoters m particular are set forth at Chien, supra at Ch. 5, Tables 2 and 3; milder agents are preferred.
  • Suitable agents for use in the method of this invention for mucosal/nasal delivery are also described in Chang, et al , Nasal Drug Delivery, “Treatise on Controlled Drug Delivery", Ch 9 and Table 3-4B thereof, (Marcel Dekker, 1992).
  • Suitable agents which are known to enhance absorption of drugs through skin are described in Sloan, Use of Solubility Parameters from Regular Solution Theory to Descnbe Partitionmg-D ⁇ ven Processes, Ch. 5, "Prodrugs: Topical and Ocular Drug Delivery” (Marcel Dekker, 1992), and at places elsewhere in the text. All of these references are incorporated herein for the sole purpose of illustrating the level of knowledge and skill in the art concerning drug delivery techniques
  • ISS-ODN may also be prepared as part of a drug delivery system, such as a posome.
  • Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large umlamellar vesicles (LUV), which range in size from 0.2-4 0 ⁇ m can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact vmons can be encapsulated withm the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al , Trends Biochem Sci., 6.11, 1981).
  • LUV large umlamellar vesicles
  • liposomes In addition to mammalian cells, liposomes have been used for delivery of polynucleotides m plant, yeast and bacterial cells.
  • a hposome In order for a hposome to be an efficient gene transfer vehicle, the following characteristics should be present- (1) encapsulation of the genes encoding the antisense polynucleotides at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannmo, et al , Bwtechniques, 6:682, 1988).
  • composition of the hposome is usually a combination of phosphohpids, particularly high-phase- transition-temperature phosphohpids, usually in combination with steroids, especially cholesterol.
  • phosphohpids or other lipids may also be used.
  • the physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
  • lipids useful in hposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholme, phosphatidylsenne, phosphatidylethanolamine, sphmgo- lipids, cerebrosides, and ganghosides. Particularly useful are diacylphosphatidylglycerols, where the hpid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
  • Illustrative phosphohpids include egg phosphatidylcholme, dipalmitoylphosphatidylcholme and distearoylphosphatidylchohne.
  • the targeting of liposomes can be classified based on anatomical and mechanistic factors.
  • Anatomical classification is based on the level of selectivity, for example, organ-specific, cell- specific, and organelle-specific.
  • Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distnbute to cells of the reticulo-endothehal system (RES) in organs which contain sinusoidal capillaries.
  • Active targeting involves alteration of the hposome by coupling the hposome to a specific hgand such as a monoclonal antibody, sugar, glycohpid, or protein, or by changing the composition or size of the hposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
  • the surface of the targeted delivery system may be modified in a variety of ways.
  • hpid groups can be incorporated into the hpid bilayer of the hposome in order to maintain the targeting hgand in stable association with the hposomal bilayer.
  • linking groups can be used for joining the hpid chains to the targeting hgand (see, e.g., Yanagawa, et al, Nuc.Acids Symp.Ser., 19:189 (1988); Grabarek, et al, Anal.Biochem., 185: 131 (1990); Staros, et al, Anal.Biochem., 156:220 (1986) and Boujrad, et al, Proc.Natl.Acad.Sci. USA, 90:5728 (1993), the disclosures of which are incorporated herein by reference solely to illustrate the standard level of knowledge m the art concerning conjugation of ohgonucleotides to lipids).
  • Targeted delivery of ISS-ODN can also be achieved by conjugation of the ISS-ODN to a the surface of viral and non-viral recombinant expression vectors, to an antigen or other hgand, to a monoclonal antibody or to any molecule which has the desired binding specificity.
  • the ISS-ODN of the invention are administered to a host using any available method and route suitable for drug delivery, including ex vivo methods (e.g., delivery of cells incubated or transfected with an ISS-ODN) as well as systemic or localized routes.
  • ex vivo methods e.g., delivery of cells incubated or transfected with an ISS-ODN
  • systemic or localized routes e.g., delivery of cells incubated or transfected with an ISS-ODN
  • methods and localized routes which direct the ISS-ODN into target tissue will be preferred in most circumstances to systemic routes of administration, both for immediacy of therapeutic effect and avoidance of oligonucleotide degradation in vivo.
  • Intranasal administration means are particularly useful m addressing respiratory conditions. Such means include inhalation of aerosol suspensions or insufflation of the polynucleotide compositions of the invention.
  • Nebulizer devices suitable for delivery of ISS-ODN compositions to the nasal mucosa, trachea and bronchioh are well-known in the art and will therefore not be described in detail here.
  • Chien, Novel Drug Delivery Systems, Ch. 5 Marcel Dekker, 1992).
  • Dermal routes of administration are useful in addressing conditions in the skm.
  • Examples of means for delivering drugs to the skin are topical application of a suitable pharmaceutical preparation, transdermal transmission, injection and epidermal administration
  • absorption promoters or iontophoresis are suitable methods.
  • those of ordinary skill in the art may wish to consult Chien, supra at Ch. 7.
  • Iontophoretic transmission may be accomplished using commercially available "patches" which deliver their product continuously via electric pulses through unbroken skin for periods of several days or more. Use of this method allows for controlled transmission of pharmaceutical compositions in relatively great concentrations, permits infusion of combination drugs and allows for contemporaneous use of an absorption promoter.
  • Ophthalmic administration involves invasive or topical application of a pharmaceutical preparation to the eye.
  • Eye drops, topical cremes and mjectable liquids are all examples of suitable mileaus for delivering drugs to the eye.
  • Systemic administration involves invasive or systemically absorbed topical administration of pharmaceutical preparations. Topical applications as well as intravenous and intramuscular injections are examples of common means for systemic administration of drugs.
  • a particular advantage of the ISS-ODN of the invention is their capacity to exert APC activating activity even at relatively mmute dosages.
  • a suitable dosage range is one which provides up to about 1-1000 ⁇ g of ISS-ODN/ml of earner in a single dosage.
  • those of ordinary skill in the clinical arts will be familiar with, or can readily ascertain, suitable parameters for administration of ISS-ODN according to the invention
  • ISS-ODN activity of ISS-ODN m the invention is essentially dose- dependent. Therefore, to increase ISS-ODN potency by a magnitude of two, each single dose is doubled m concentration. Clinically, it may be advisable to administer the ISS-ODN in a low dosage (e.g., about 1 ⁇ g/ml to about 50 ⁇ g/ml), then increase the dosage as needed to achieve the desired therapeutic goal.
  • a target dosage of ISS-ODN can be considered to be about 1-10 ⁇ M m a sample of host blood drawn withm the first 24-48 hours after administration of ISS-ODN. Based on current studies, ISS-ODN are believed to have little or no toxicity at these dosage levels.
  • all dosmg decisions he withm the judgment of the clinician and, for applications where the ISS-ODN is administered as part of a vaccination protocol, must take into account the limits imposed by that protocol.
  • kits are also provided by the invention.
  • kits may include any or all of the following: ISS-ODN (conjugated or unconjugated); a pharmaceutically acceptable carrier (may be pre-mixed with the ISS-ODN) or suspension base for reconstituting lyophihzed ISS-ODN; additional medicaments; a sterile vial for each ISS-ODN and additional medicament, or a single vial for mixtures thereof; dev ⁇ ce(s) for use in delivering ISS-ODN to a host; assay reagents for detecting indicia that the APC activating effects sought have been achieved in treated animals and a suitable assay device.
  • ISS-ODN APC-Activators Endotoxm free ( ⁇ 1 ng/mg DNA) phosphorothioate single stranded ODNs (T ⁇ link, San Diego, CA) were used in all the expenments descnbed in these Examples.
  • the sequence of the ISS-ODN was 5'- TGACTGTGAACGTTCGAGATGA-3'.
  • An inactivated ISS-ODN (“M-ODN”) was also synthesized for use as a control; its sequence was 5 '-TGACTGTG AAGGTTAGAG ATG A-3 ' .
  • the underline indicates the ISS (CpG) motif and its corresponding alteration.
  • Plasmid pUC19 (which includes two copies of an AACGTT ISS-ODN core hexamer) was punfied with the Qiagen MaxiPrep Kit (Chastworth CA). Activity was abolished in pUC19 by methylatmg the CpG moiety by incubating the plasmid with CpG methylase (M.Sss I, New England Biolabs,
  • ISS-ODN induce in vitro up-regulation of a distinctive profile of cell surface markers on splenic B cells
  • mice and wild type (wt) control mice (C57B1/6) mice (six to ten weeks of age) were purchased from The Jackson Laboratones (Bar Harbor, ME) TCR-OVA (DOl 1.10) transgenic (TG) mice are produced on the BALB/c background to be responsive to a model antigen (ovalbumm, or
  • OVA Und Broide
  • Splenic T cells and APCs were prepared from BALB/c TCR-OVA TG mice. The animals were injected l.d. with salme, ISS-ODN (50 ⁇ g/mouse) or M-ODN (50 ⁇ g/mouse) on days 0 and 7 On day 14 mice were sacrificed and the spleens were harvested as previosuly descnbed (23) to obtain APCs.
  • splenocytes were treated with ant ⁇ -CD8 abs (3.155) and ant ⁇ -CD4 abs (RL172) followed by incubation with guinea pig complement (Pel -Freeze, Rogers, Arkansas) as described (24), and fixed with MMC (50 ⁇ g/ml, 30 mm. at 37°C) prior to being used as accessory cells.
  • Splenocytes were obtained from naive TCR-OVA TG mice and purified for T cells by negative selection using the following antibody cocktail: Jl ID (anti-HSA), CA4.12 (anti-la), RA36B2 (anti- B220), M5.114 (anti-la, isotype IgG2a), MAR.18 (mouse anti-Rat IgG) with guinea pig complement.
  • the resultant T-cell preparations >95% punty by FACS staining
  • lOVwell were mixed with the same number of accessory cells and hen egg ovalbumm (OVA, 10 ⁇ g/ml, grade 5, Sigma) for 3 or 4 days.
  • B7-2, CD40, ICAM-1, CD16/32, IFN- ⁇ R and IL-2R A slight up-regulation was observed for B7-1.
  • CD23 expression was down-regulated, while no differences in the expression of CD49b,
  • CDld ( Figure 1), CD49a, CD49c-f, IL-1R, and IL-6 R (data not shown) were observed the ISS- ODN vs. Media or M-ODN treated cells.
  • the cell surface profile induced by ISS stimulation of punfied B splenocytes was similar to that observed for B cells (B220 + ) from ISS stimulated splenocytes.
  • stimulation with LPS resulted in a different pattern of activation, e.g., a stronger induction of B7-1 with less of an effect on CD23
  • the effect of LPS on other cell surface markers was similar to that observed for ISS-ODN but with different intensity (Figure 1)
  • ISS-ODN induced a similar activation profile on penpheral blood B220 + cells as descnbed for splenic B220 + B cells in vitro.
  • ISS-ODN induces in vivo up-regulation of cell surface markers on splenic B cells
  • BABL/c mice were injected with ISS-ODN, M-ODN (50 ⁇ g/50 ⁇ l saline/mouse) or salme l.p. Mice were sacrificed at days 2, 7, and 21 after the injection and the splenic B220 + B cells were stained and analyzed by FACS.
  • ISS-ODN induces up-regulatwn of a distinctive profile of cells surface markers in vitro on bone-marrow-derived-macrophages (BMDM)
  • Bone marrow cells were flushed from the femurs of 4-to-8-week old female BALB/c mice, washed once with RPMI media and cultured in 145 mm pern dishes (Greiner Labortechnik, Kremsmunster, Austria).
  • the culture medium consisted to EMEM (Irvine Scientific) supplemented with 10% FBS (Gemmi Bioproducts Inc.), 2 mM L-glutamme (Bio-Whitaker), 1 mM sodium pyruvate (Bio- Whitaker), 30 ng recombinant murme M-CSF (R&D systems, Minneapolis, MN), 100 U pemcillm/ml (Bio-Whitaker), 100 ⁇ g streptomycin (Bio-Whitaker), 0.125 mg/ml amphotencm B (Bio-Whitaker) and 30% L-cell conditioned media obtained by incubation of L929 cells with the media described above for 1 week.
  • the cells had acquired macrophage-hke morphology.
  • Cells then were washed and re-cultured with media containing ISS- ODN (1 ⁇ g/ml), M-ODN (1 ⁇ g/ml), LPS (5 ⁇ g/ml), pUC19 (10 ⁇ g/ml) or methyl-pUC19 (10 ⁇ g/ml). After 48 hours the cells were harvested by incubation with ice-cold PBS and prepared for either FACS analysis or a cytokine release assay.
  • BMDM bone marrow derived macrophages
  • mice secreted 17 fold more IL-6 and 43 fold more IL-12 than did BALB/c splenocytes upon stimulation with ISS-ODN, suggesting that these cells play a major role m the generation of the cytokine milieu induced by ISS-ODN-based DNAs in vivo.
  • ISS-treated APCs splenocytes
  • TCR-OVA TG mice were injected with ISS-ODN, M-ODN or saline.
  • TCR-OVA TG mice with naive T cells (2 mice/group) were injected mtradermally (i.d.) At the base of the tail with ISS- ODN (50 ⁇ g/mouse), M-ODN (50 ⁇ g/mouse), or salme on days 0 and 7.
  • Mice were killed at day 14 for T cell proliferation and cytokine release assays. Twelve weeks after protein injection the mice were sacrificed.
  • BALB/c mice (4 mice/group) were injected i.d.
  • mice were co-injected i.d. at day 0 with either ISS-ODN (50 ⁇ g/mouse) or M-ODN (50 ⁇ g/mouse) plus ⁇ -gal (10 ⁇ g/mouse) or with ⁇ -gal alone (10 ⁇ g/mouse, at day 0). Mice were again sac ⁇ fied twelve weeks after protein injection.
  • APCs from ISS-ODN injected mice induced 4 fold more T cell proliferation (at 30 ⁇ g/ml of OVA) than APCs obtained from salme or M-ODN treated mice ( Figure 6A), indicating an enhanced capacity of APCs obtained from treated mice to stimulate naive T cells.
  • ISS-ODN delivery prior to antigen administration created both an appropriate cytokine milieu ( Figure 2) and induced up-regulation of various surface molecules on APCs for a penod of at least 3 weeks ( Figure 2).
  • Figure 2 T cell activation and Thl differentiation responsive to a subsequently administered antigen was enhanced.
  • ISS-ODN or M-ODN were injected into BALB/c mice 3 days pnor to antigen ( ⁇ -gal) administration (pre-pnmmg) and the subsequent immune response was compared to ISS/ ⁇ -gal co-injection as well as to injection of ⁇ -gal alone.
  • ISS-ODN pre-pnmmg resulted in enhanced T cell proliferation to ⁇ -gal (2 fold over ISS/ ⁇ -gal co-injection; Figure 7B) and in enhanced ⁇ -gal specific IFN- ⁇ production (6 fold over ISS/ ⁇ -gal connection) (Figure 7A).
  • ISS pre-pnmmg amplified the immune response m general and the Thl response in particular to the subsequently injected antigen
  • EXAMPLE VI B cell surface molecules are induced by pUC19
  • pUC19 To analyze the primary effect of pDNA on cytokine release we incubated BALB/c splenocytes with pUC19 or methyl-pUC19 and followed the levels of the cytokmes the supematants. As shown in Figure 4, incubation of pUC19 induced a similar profile of cytokmes to that induced by ISS-ODN whereas methyl-pUC 19 did not.
  • mouse splenocytes were incubated or transfected with pUC19 for 48 hours pnor to antibody staining and analysis by FACS.
  • mice splenocytes with pUC19 (10 ⁇ g/ml) and mefhyl-pUC19 (10 ⁇ g/ml) were performed with DOTAP (Boehnnger Manheim).
  • Mouse spleen cells were resuspended at 3xl0 5 cells/ml in teflon tubes and incubated with a mix of plasmid and DOTAP for 4 hours at 37 C, and 5% C0 2 . Cell were washed twice and resuspended at 2x10 6 cells/ml in culture media. After 48 hours of incubation, the supematants were collected for cytokine ELISA and the cells harvested and stained for FACS analysis as described above. Additionally, FACS analysis of splenocytes incubated with pUC19 (lO ⁇ g/ml) and methyl-pUC19 (10 ⁇ g/ml) was made under the same conditions mentioned above without DOTAP.
  • transfection with pUC19 induced a similar cell surface expression profile on B splenocytes as did incubation with ISS-ODN ( Figure 1) while incubation with pUC19 resulted in a weak to marginal induction of cell surface molecules on these cells.
  • EXAMPLE VII Induction of cell surface molecules on B cells is not dependent upon B cell proliferation
  • splenocytes were gamma irradiated or treated with MMC and then incubated with ISS-ODN or M-ODN.
  • the expression of surface markers was analyzed 48 hours later. The inhibition of proliferation was confirmed by the lack of BrdU incorporation.
  • munne spleen cells were gamma irradiated (1500 rad) or treated with MMC (50 ⁇ g/ml for 30 mm. At 37°C).
  • ISS-ODNs still modify the expression of surface molecules on B cells
  • splenocytes were incubated with ISS-ODN (1 ⁇ g/ml), M-ODN (1 ⁇ g/ml), LPS (5 ⁇ g/ml) or media alone. After a 48 hour incubation, cells were stained for expression of B220 versus cell surface markers. Additionally, the cells were incubated with BrdU (15 ⁇ g/ml, Boehnnger Mannheim, Indianapolis, IN) in order to check the inhibition of proliferation after the different treatments.
  • BrdU 15 ⁇ g/ml, Boehnnger Mannheim, Indianapolis, IN
  • ISS-ODN up-regulates the expressiom of cell surface molecules despite the inhibition of the B cell prohferative response of ISS either by irradiation or by MMC treatment, indicating that the observed expression pattern is not the consequence of the ISS induced B cell mitogenesis.

Abstract

L'invention concerne des méthodes permettant d'améliorer les capacités de présentation d'antigène de cellules capables de présentation d'antigène en mettant ces cellules en contact avec un oligonucléotide immunostimulateur. Par ce contact, les cellules de présentation d'antigène traitées sont amenées à absorber l'antigène (par régulation positive de l'expression de Fc R), à présenter l'antigène (par régulation positive de l'expression de MHC de classe I et II ainsi que CD1d), à produire des facteurs costimulateurs (B7 et CD40), à fournir une adhésion intercellulaire (par régulation positive de l'expression de ICAM) et à augmenter la production simulatrice de la cytokine Th1 (par exemple, IL-12), le tout à des niveaux plus élevés que ne le permet la mise en contact des cellules de présentation d'antigène uniquement avec l'antigène. L'invention concerne également des méthodes d'utilisation de ces cellules améliorées de présentation d'antigène afin de stimuler la réaction des lymphocytes à l'antigène, ainsi que des compositions de cellules de présentation d'antigène présentant une activité améliorée.
PCT/US2000/009664 1999-04-15 2000-04-11 Methodes et compositions destinees a la potentialisation de la presentation de l'antigene au moyen de cellules de presentation d'antigene WO2000062787A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46426/00A AU4642600A (en) 1999-04-15 2000-04-11 Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29227899A 1999-04-15 1999-04-15
US09/292,278 1999-04-15

Publications (1)

Publication Number Publication Date
WO2000062787A1 true WO2000062787A1 (fr) 2000-10-26

Family

ID=23123985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009664 WO2000062787A1 (fr) 1999-04-15 2000-04-11 Methodes et compositions destinees a la potentialisation de la presentation de l'antigene au moyen de cellules de presentation d'antigene

Country Status (2)

Country Link
AU (1) AU4642600A (fr)
WO (1) WO2000062787A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019900A1 (fr) * 2002-08-27 2004-03-11 Societe Des Produits Nestle Prevention ou traitement d'une lesion de l'epithelium ou de la perte des cheveux
EP1420829A2 (fr) * 2001-08-07 2004-05-26 Dynavax Technologies Corporation Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
EP1501359A2 (fr) * 2001-08-03 2005-02-02 Celldex Therapeutics, Inc. Compositions contenant des oligonucleotides immunostimulants et leurs utilisations pour amplifier des immunotherapies declenchees indirectement par le recepteur fc
WO2004101776A3 (fr) * 2003-05-14 2005-05-12 Univ Debrecen Nouveaux emplois des modulateurs du recepteur ppar et cellules presentant l'antigene a usage professionnel manipulees par lesdits modulateurs
US7713529B2 (en) 1994-07-15 2010-05-11 University Of Iowa Research Foundation Methods for treating and preventing infectious disease
US7758876B2 (en) 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7919477B2 (en) 2000-01-14 2011-04-05 The United States Of America As Represented By The Department Of Health And Human Services Multiple CpG oligodeoxynucleotides and their use to induce an immune response
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
US8030285B2 (en) 1999-04-12 2011-10-04 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8114848B2 (en) 1994-07-15 2012-02-14 The United States Of America As Represented By The Department Of Health And Human Services Immunomodulatory oligonucleotides
US8202688B2 (en) 1997-03-10 2012-06-19 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAKOB ET. AL.: "Activation of cutaneous dendritic cells by CpG containing oliodeoxynucleotides: a role for dendritic cells in the augmentation of th1 responses by immunostimulatory DNA.", J. IMMUNOL., vol. 161, pages 3042 - 3049, XP002928254 *
LIPFORD ET. AL.: "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.", EUR. J. IMMUNOL, vol. 27, December 1997 (1997-12-01), pages 3420 - 3426, XP002928255 *
WOOLDRIDGE ET. AL.: "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the effecacy of monoclonal antibody theraphy of lymphoma.", BLOOD, vol. 89, no. 8, 15 April 1997 (1997-04-15), pages 2294 - 2998, XP002928253 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713529B2 (en) 1994-07-15 2010-05-11 University Of Iowa Research Foundation Methods for treating and preventing infectious disease
US7888327B2 (en) 1994-07-15 2011-02-15 University Of Iowa Research Foundation Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions
US8008266B2 (en) 1994-07-15 2011-08-30 University Of Iowa Foundation Methods of treating cancer using immunostimulatory oligonucleotides
US8309527B2 (en) 1994-07-15 2012-11-13 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US8258106B2 (en) 1994-07-15 2012-09-04 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8114848B2 (en) 1994-07-15 2012-02-14 The United States Of America As Represented By The Department Of Health And Human Services Immunomodulatory oligonucleotides
US8202688B2 (en) 1997-03-10 2012-06-19 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US8389495B2 (en) 1999-04-12 2013-03-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Olioodeoxynucleotide and its use to induce an immune response
US8030285B2 (en) 1999-04-12 2011-10-04 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8741869B2 (en) 1999-04-12 2014-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8232259B2 (en) 2000-01-14 2012-07-31 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple CpG oligodeoxynucleotide and their use to induce an immune response
US7919477B2 (en) 2000-01-14 2011-04-05 The United States Of America As Represented By The Department Of Health And Human Services Multiple CpG oligodeoxynucleotides and their use to induce an immune response
EP1501359A4 (fr) * 2001-08-03 2007-04-18 Celldex Therapeutics Inc Compositions contenant des oligonucleotides immunostimulants et leurs utilisations pour amplifier des immunotherapies declenchees indirectement par le recepteur fc
EP1501359A2 (fr) * 2001-08-03 2005-02-02 Celldex Therapeutics, Inc. Compositions contenant des oligonucleotides immunostimulants et leurs utilisations pour amplifier des immunotherapies declenchees indirectement par le recepteur fc
EP1420829A4 (fr) * 2001-08-07 2006-05-17 Dynavax Tech Corp Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
EP1420829A2 (fr) * 2001-08-07 2004-05-26 Dynavax Technologies Corporation Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
US8586555B2 (en) 2001-08-07 2013-11-19 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
JP2005527465A (ja) * 2001-08-07 2005-09-15 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
JP2006511462A (ja) * 2002-08-27 2006-04-06 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 上皮組織損傷又は脱毛症の予防又は治療
WO2004019900A1 (fr) * 2002-08-27 2004-03-11 Societe Des Produits Nestle Prevention ou traitement d'une lesion de l'epithelium ou de la perte des cheveux
AU2003266313B2 (en) * 2002-08-27 2009-10-22 Societe Des Produits Nestle S.A. Preventing or treating epithelial tissue damage or hair loss
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
US8481055B2 (en) 2002-11-01 2013-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7758876B2 (en) 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
WO2004101776A3 (fr) * 2003-05-14 2005-05-12 Univ Debrecen Nouveaux emplois des modulateurs du recepteur ppar et cellules presentant l'antigene a usage professionnel manipulees par lesdits modulateurs

Also Published As

Publication number Publication date
AU4642600A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
AU757175B2 (en) Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US7208478B2 (en) Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US7566702B2 (en) Immunostimulatory oligonucleotide multimers
US20060014713A1 (en) Immunostimulatory oligonucleotide multimers
EP2341059A1 (fr) Composés d'oligonucléotides de régulation immune (IRO) permettant de moduler une réponse immune fondée sur un récepteur de type toll
KR20050009697A (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
WO2000062787A1 (fr) Methodes et compositions destinees a la potentialisation de la presentation de l'antigene au moyen de cellules de presentation d'antigene
EP1119375A1 (fr) Procedes et adjuvants stimulant l'immunite des muqueuses
EP2588143B1 (fr) Nouveaux agonistes du récepteur toll-like 3 et procédés pour les utiliser
Kuramoto et al. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex
Nichani et al. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep
AU2003203948B2 (en) Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
AU768178B2 (en) Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
Hasan Development of novel DNA vaccine and immunotherapeutic approaches
Terui et al. Novel Roles of CpG Oligodeoxynucleotides as

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP